John Wilkerson

John Wilkerson is a Washington correspondent at STAT who covers the politics of health care, with a focus on how decisions in Washington reshape insurance, drug markets, and access to care. His work is distinguished by close attention to the mechanics of federal health programs and the power struggles around them, rather than clinical science or hospital stories. He is the author of STAT’s twice-weekly D.C. Diagnosis newsletter, an insider’s guide to the politics of health and medicine that tracks the deals, personnel moves, and policy experiments driving the U.S. health system.

Politics of health care and D.C. Diagnosis

Wilkerson’s central frame is the national **politics of health care**, and he writes consistently from the vantage point of Washington’s legislative and regulatory machinery.

D.C. Diagnosis is described as an insider’s guide to the politics of health and medicine, delivered on Tuesdays and Thursdays, and his recent editions center on topics like FDA leadership, Affordable Care Act premiums, and the stability of employer-based coverage.

In one recent D.C. Diagnosis piece on “The crumbling employer-based health insurance system,” he examines how workplace insurance is weakening and what that means for future policy fights over how Americans get coverage.

His election-year work shows the same emphasis on policy detail over campaign rhetoric. In a health care policy voter guide, he breaks down where major candidates stand on abortion, the Affordable Care Act, drug pricing reforms under the Inflation Reduction Act, and related issues, framing the article as a tool for understanding how different administrations would reshape health policy. In a broader health news roundup, he and a colleague explain how Harris and Trump are framing health care deals, again tying political messaging back to concrete policy and program changes.

Earlier coverage of President Trump’s tax-cutting plan details how the bill’s “attendant health care measures” would cut government spending, discourage Medicaid expansion, limit abortion coverage, and restrict coverage for immigrants, underscoring his focus on the downstream consequences of fiscal and ideological decisions.

Medicare, Medicaid, and drug pricing fights

Wilkerson’s reporting on **Medicare, Medicaid, and drug pricing** is a major strand of his beat, with repeated deep dives into how federal benefit design intersects with pharmaceutical strategy. In coverage of Trump’s low-cost GLP-1 obesity drug proposal, he explains how the plan would create a new Medicare pathway for these drugs and why it is a likely boost for companies like Eli Lilly and Novo Nordisk.

He treats the proposal as more than a campaign talking point, unpacking the structure of a temporary Medicare program for obesity drugs, the difficulty of unwinding such a program once in place, and the budget and market implications for the larger GLP-1 class.

He regularly connects Medicare policy to insurer behavior and long-term cost trends. In a piece on “A suspicious denial pattern in Medicare Advantage,” he zeroes in on prior authorization denials and links them to broader concerns about prescription drug costs and issues raised in the Medicare trustees report. That article uses individual cases as entry points into how Medicare Advantage plans manage risk and spending, and how regulators might respond. His STAT Plus exclusives extend this work to specific pricing mechanisms, including coverage of Trump’s “most-favored nation” drug pricing policy and reporting on drugmakers forming new lobbying groups to influence pricing and reimbursement decisions. He has also written about health savings account companies that “struck it big” under Trump-era policy, showing how niche financial instruments sit inside larger federal health benefit strategies.

In multi-topic health news coverage, Wilkerson contributes segments on Medicare drug prices alongside stories on mpox, extreme heat, and disability issues, reinforcing that he treats drug pricing and public program costs as part of a wider ecosystem of stress on the health system. Across these pieces he writes in practical terms about who pays for drugs, who sets prices, and which political coalitions win or lose from each change.

Insurers, employer coverage, and billing codes

Another recurring focus is the behavior of **insurers and employer-based coverage**, and the technical infrastructure that underpins payment. In his newsletter story on “The crumbling employer-based health insurance system,” he analyzes how rising premiums and changing labor markets erode the traditional model of getting insurance through work, and what that implies for future reforms.

He treats employer coverage as a political institution as much as a financial one, describing how its decline feeds arguments for alternative models, including expanded public programs.

In “A suspicious denial pattern in Medicare Advantage,” he scrutinizes prior authorization and claim denial practices, highlighting patterns that raise oversight concerns and suggesting how those practices interact with the design of Medicare Advantage plans.

His reporting emphasizes the relationship between insurer incentives, federal rules, and patient experiences, rather than presenting denials as isolated anecdotes. In “A new attack on AMA’s billing codes,” he explains how CPT billing codes structure physician payment and reports on political and regulatory scrutiny of those codes, focusing on why policymakers see them as a lever for controlling costs.

These pieces show a reporter comfortable with arcane payment systems and determined to translate them into clear narratives about power, profit, and access.

FDA leadership, clinical trials, and GLP-1 scrutiny

Wilkerson also tracks **FDA leadership and clinical trial policy**, often linking personnel decisions to regulatory outcomes. He has written on praise for FDA’s acting commissioner, exploring how temporary leadership shapes agency priorities and industry confidence. In another D.C. Diagnosis edition, he covers the White House’s review of finalists for the permanent FDA commissioner role alongside surging Affordable Care Act plan premiums, pairing regulatory succession with market pressures on coverage. This work presents FDA leadership as one more political battlefield that directly affects how drugs and devices move to market.

His GLP-1 coverage goes beyond pricing and benefits. In an exclusive story on a “mystery man” receiving an experimental GLP-1 drug, he reports on congressional interest and links the case to concerns about Chinese biotech and cross-border research ties.

The article uses an individual patient story to probe how lawmakers think about novel obesity drugs, foreign partnerships, and national security lenses on biomedical innovation. He has also covered lawmakers’ efforts to protect clinical trial diversity requirements from broader crackdowns on diversity, equity, and inclusion policies, highlighting the tension between political movements and scientific standards.

That reporting frames diversity mandates as a concrete regulatory tool at risk in wider ideological fights.

Taken together, these stories show Wilkerson following drugs and trials from committee rooms and agency offices rather than lab benches, consistently mapping how political decisions about leadership, security, and equity shape what research gets done and who benefits.